Semaglutide

Clinical evidence summary

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated significant efficacy in managing type 2 diabetes mellitus, chronic weight management, and reducing cardiovascular risk. Its mechanism of action involves stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety, all of which contribute to improved glycemic control and weight loss.

In the context of type 2 diabetes, semaglutide has been shown to significantly reduce HbA1c levels and body weight. Clinical trials have established its effectiveness in achieving glycemic targets, often in combination with other antidiabetic agents or as monotherapy. The cardiovascular benefits of semaglutide have been particularly notable, with studies demonstrating a reduction in major adverse cardiovascular events (MACE) in individuals with type 2 diabetes and established cardiovascular disease. This finding led to an expansion of its label for cardiovascular risk reduction.

For chronic weight management, semaglutide has emerged as a highly effective therapeutic option. Clinical trials have shown substantial and sustained weight loss in individuals with obesity or overweight, with or without comorbidities. The degree of weight loss achieved with semaglutide is often greater than that observed with other pharmacotherapies for weight management.

The SELECT trial (NCT03548935) was a pivotal study that investigated the cardiovascular outcomes of semaglutide in adults with overweight or obesity and established cardiovascular disease. The results of this trial provided strong evidence for the cardiovascular benefits of semaglutide, supporting its use for cardiovascular risk reduction in this population. NCT03548935

The development and approval of semaglutide by Novo Nordisk in 2017 marked a significant advancement in the treatment of metabolic disorders. Its availability in both injectable and oral formulations has enhanced patient adherence and treatment options.

Further research continues to explore the full therapeutic potential of semaglutide, including its effects on other metabolic parameters and its role in various patient populations. The long half-life of approximately 7 days allows for convenient once-weekly or daily dosing, depending on the formulation.

Established dosing protocols

Semaglutide is available in multiple formulations, each with specific dosing regimens:

• Injectable Semaglutide (Ozempic): This formulation is administered subcutaneously once weekly. The starting dose is typically 0.25 mg, which is then escalated over several weeks to a maintenance dose of 0.5 mg, 1 mg, or 2 mg once weekly, based on glycemic control and tolerability.
• Injectable Semaglutide (Wegovy): This formulation is also administered subcutaneously once weekly and is specifically indicated for chronic weight management. The starting dose is 0.25 mg, with dose escalation over several weeks to a target maintenance dose of 2.4 mg once weekly.
• Oral Semaglutide (Rybelsus): This formulation is taken orally once daily. The starting dose is typically 3 mg daily for the first four weeks, followed by an increase to 7 mg daily. For individuals requiring additional glycemic control, the dose can be further increased to 14 mg daily. Oral semaglutide should be taken on an empty stomach with no more than 120 mL of water, and patients should wait at least 30 minutes before eating or drinking anything else or taking other oral medications.

Dose adjustments should be made under the guidance of a healthcare professional, considering individual patient response, tolerability, and therapeutic goals. The long half-life of approximately 7 days contributes to the sustained therapeutic effect of semaglutide, allowing for infrequent dosing.

Safety profile and contraindications

Semaglutide is associated with a black-box warning regarding the potential for thyroid C-cell tumors observed in rodent studies. While the relevance of this finding to humans is not fully established, it necessitates caution and contraindicates the use of semaglutide in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Common side effects associated with semaglutide therapy include gastrointestinal disturbances such as nausea, vomiting, diarrhea, constipation, and abdominal pain. These side effects are often dose-dependent and tend to be transient, improving over time. However, they can be severe in some individuals and may lead to discontinuation of the medication.

Other potential adverse events include:

• Pancreatitis: There have been reports of acute pancreatitis in patients treated with GLP-1 receptor agonists, including semaglutide. Patients should be advised to seek immediate medical attention if they experience severe abdominal pain, which may radiate to the back, with or without vomiting.
• Hypoglycemia: While semaglutide itself has a low risk of causing hypoglycemia when used as monotherapy, the risk can be increased when it is used in combination with other medications known to cause hypoglycemia, such as sulfonylureas or insulin.
• Diabetic Retinopathy Complications: In patients with a history of diabetic retinopathy, rapid improvement in glycemic control has been associated with a temporary worsening of diabetic retinopathy.
• Renal Impairment: Cases of acute kidney injury and worsening chronic renal failure have been reported in patients treated with GLP-1 receptor agonists, sometimes requiring dialysis. These events have been associated with gastrointestinal adverse reactions.
• Injection Site Reactions: For injectable formulations, localized reactions such as redness, itching, or swelling at the injection site may occur.

Contraindications also include known hypersensitivity to semaglutide or any of its excipients.

Drug interactions and precautions

Semaglutide's effect on gastric emptying may influence the absorption of other orally administered medications. Caution should be exercised when co-administering semaglutide with drugs that have a narrow therapeutic index, particularly those that require critical absorption levels. Patients taking oral contraceptives should be advised that the contraceptive effect of combined oral contraceptives may be diminished when semaglutide is administered, and back-up or alternative methods of contraception should be used during treatment and for at least 4 weeks after the last dose.

When semaglutide is used in combination with medications known to cause hypoglycemia, such as sulfonylureas or insulin, a reduction in the dose of these concomitant medications may be necessary to decrease the risk of hypoglycemia.

Patients with a history of pancreatitis should be closely monitored. The potential for drug interactions with other medications affecting gastric motility or absorption should be considered.

Due to the risk of diabetic retinopathy complications, particularly in patients with a history of this condition, careful monitoring is advised, especially during periods of rapid glycemic control improvement.

Monitoring during therapy

Regular monitoring is essential to assess the efficacy and safety of semaglutide therapy. Healthcare providers should monitor:

• Glycemic Control: For patients with type 2 diabetes, regular monitoring of blood glucose levels and HbA1c is crucial to assess the effectiveness of semaglutide in achieving glycemic targets.
• Body Weight: For patients using semaglutide for chronic weight management, regular assessment of body weight is necessary to evaluate treatment response.
• Renal Function: Renal function should be monitored, particularly in patients who experience severe gastrointestinal adverse reactions, to detect any signs of acute kidney injury or worsening renal impairment.
• Pancreatic Enzymes: While not routinely recommended, monitoring of pancreatic enzymes may be considered in patients with risk factors for pancreatitis or if symptoms suggestive of pancreatitis arise.
• Thyroid Function: Although not a routine monitoring parameter for all patients, individuals with a history of thyroid disease or those experiencing symptoms of thyroid dysfunction should be evaluated.
• Vision: Patients with a history of diabetic retinopathy should have regular eye examinations to monitor for any changes.

Patients should be educated on the signs and symptoms of potential adverse events, such as pancreatitis, severe gastrointestinal distress, and hypoglycemia, and instructed to report them promptly to their healthcare provider.

Who should NOT use this

Semaglutide is contraindicated in individuals with:

• A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Known hypersensitivity to semaglutide or any of its excipients.
• Patients with a history of pancreatitis may require careful consideration and risk-benefit assessment before initiating therapy.

The use of semaglutide in pregnant or breastfeeding women is generally not recommended due to potential risks to the fetus and infant. Patients should discuss their plans for pregnancy or breastfeeding with their healthcare provider before starting or continuing semaglutide therapy.

Individuals with severe gastrointestinal disease, such as gastroparesis, should use semaglutide with caution, as it may exacerbate these conditions.